Lifeward Ltd. (LFWD)
| Market Cap | 21.53M +106.1% |
| Revenue (ttm) | 20.92M -17.7% |
| Net Income | -25.87M |
| EPS | -19.24 |
| Shares Out | 2.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,043 |
| Open | 7.65 |
| Previous Close | 7.57 |
| Day's Range | 7.55 - 7.81 |
| 52-Week Range | 4.14 - 10.56 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 20.00 (+161.44%) |
| Earnings Date | Aug 14, 2026 |
About LFWD
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG ... [Read more]
Financial Performance
In 2025, Lifeward's revenue was $22.03 million, a decrease of -14.14% compared to the previous year's $25.66 million. Losses were -$19.91 million, -31.19% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LFWD stock is "Buy." The 12-month stock price target is $20.0, which is an increase of 161.44% from the latest price.
News
Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of c...
Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward's strategy to br...
Lifeward files to sell 2.07M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.07M ordinay shares. The company is not selling any shares under…
Lifeward Registration statement: Registration filing
Lifeward filed a registration statement on August 3, 2026, providing details about a securities offering with the SEC.
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial ...
Lifeward appoints Keith Rose as chief medical officer
Lifeward (LFWD) announced the appointment of Keith Rose as chief medical officer. Rose, who previously served as VP, medical affairs and medical director, Neurosciences at Lifeward, will lead the comp...
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic diseas...
Lifeward Earnings Call Transcript: Q1 2026
Revenue declined year-over-year due to AlterG shipment delays, but ReWalk sales grew 11% and international expansion continued. Liquidity improved with new financing and the Oratech acquisition, while operational efficiency gains offset lower revenue.
Lifeward Earnings release: Q1 2026
Lifeward released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Lifeward Quarterly report: Q1 2026
Lifeward has published its Q1 2026 quarterly earnings report on May 15, 2026.
Lifeward Reports First Quarter 2026 Financial Results
Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery ™ biomed technology , with lea...
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of co...
Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018 , spanning broad patient profiles...
Lifeward files to sell 7.26M ordinary shares for holders
17:02 EDT Lifeward (LFWD) files to sell 7.26M ordinary shares for holders
Lifeward Registration statement: Registration filing
Lifeward filed a registration statement on April 27, 2026, providing details about a securities offering with the SEC.
Lifeward closes strategic partnership agreement with Oramed
Lifeward (LFWD) announced that it has closed on the company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals (ORMP). The transaction has positioned Lifeward as a dive...
Lifeward Successfully Closes on Strategic Partnership with Oramed
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Lifeward price target adjusted to $10 from $4.50 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on Lifeward (LFWD) to $10 from $4.50 and keeps a Buy rating on the shares. The firm cites the company’s 1-12 reverse stock…
Lifeward Earnings Call Transcript: Q4 2025
Lifeward Annual report: Q4 2025
Lifeward has published its Q4 2025 annual report on March 18, 2026.
Lifeward Earnings release: Q4 2025
Lifeward released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Lifeward reports Q4 adjusted EPS ($2.85) vs. ($4.54) last year
Reports Q4 revenue $5.1M vs. $7.5M last year. “We are entering 2026 with a pivotal transaction that establishes Lifeward (LFWD) as a diversified biomedical innovation company positioned for long-term ...
Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction r eceives s hareholder a pproval ; Lifeward ...
Lifeward receives shareholder approval to close on partnership with Oramed
Lifeward (LFWD) announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Company’s previously announced strategic partnership agreemen...
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Or...